Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CanSino Moving Coronavirus Vaccine To Phase III

Executive Summary

CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.

You may also be interested in...



Coronavirus Update: GSK Signs Non-Coronavirus Deal With CureVac On mRNA Vaccines

Deal brings in new funding and commercial partner for CureVac, and gives GSK greater stake in fast-developing mRNA field.

Coronavirus Update: 'We Are Racing Against The Virus, Not America,' Says China’s Vaccine Frontrunner

Plus new biotech company Adagio Therapeutics has been launched with a $50m series A financing to advance its coronavirus antibodies as therapeutics and prophylactics.

Congressional Democrats Press US FDA For Transparency In Review Of COVID-19 Vaccines

FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel